Brief: Lantern Pharma Announces Formation Of Starlight Therapeutics To Advance Transformative Therapies For Central Nervous System and Brain Cancers
06/03/2023 13:13
March 6 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FORMATION OF STARLIGHT
THERAPEUTICS TO
ADVANCE TRANSFORMATIVE THERAPIES FOR CNS (CENTRAL NERVOUS
SYSTEM) AND BRAIN CANCERS
* LANTERN PHARMA INC - CLINICAL TRIALS IN ADULT AND
PEDIATRIC CNS
CANCER INDICATIONS ARE ANTICIPATED FOR LATE 2023 AND EARLY 2024.
Source text for Eikon: ID:nBw9PZmCVa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview